CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Ming, Yue ^a   Hu, Xiangnan ^a   Song, Ying ^a   Liu, Zhiguo ^a   Li, Jibin ^a   Gao, Rufei ^a   Zhang, Yuyao ^a   Mei, Hu ^b   Guo, Tingwang ^b   Xiao, Ling ^b   Wang, Bochu ^b   Wu, Chaodong ^c   Xiao, Xiaoqiu ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

^c TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 TERT BUTOXYCARBONYLMETHYL 5 [4 [2 [N METHYL N (2 PYRIDYL)AMINO]ETHOXY]BENZYL]THIAZOLIDINE 2,4 DIONE; ADIPONECTIN; ARGINASE 1; CMHX 008; GLITAZONE DERIVATIVE; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCOPROTEIN P 15095; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3-TERT-BUTOXYCARBONYLMETHYL-5-(4-(2-(N-METHYL-N-(2-PYRIDYL)AMINO)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; AMINOPYRIDINE DERIVATIVE; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT;

3T3 CELL LINE; ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; AP2 GENE; ARTICLE; CELL DIFFERENTIATION; CHRONIC INFLAMMATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE; GENE EXPRESSION REGULATION; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUT4 GENE; HISTOPATHOLOGY; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LOW FAT DIET; MALE; MOLECULAR DOCKING; MOUSE; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STRUCTURE ACTIVITY RELATION; UPREGULATION; WEIGHT CHANGE; ADVERSE EFFECTS; AGONISTS; ANIMAL; C57BL MOUSE; CELL POLARITY; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; DYSLIPIDEMIAS; HUMAN; MACROPHAGE; PATHOLOGY; PHYSIOLOGY; TRANSCRIPTION INITIATION; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOSE TISSUE, WHITE; AMINOPYRIDINES; ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL DIFFERENTIATION; CELL POLARITY; DIET, HIGH-FAT; DRUG EVALUATION, PRECLINICAL; DYSLIPIDEMIAS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSCRIPTIONAL ACTIVATION;

EID: 84903893789     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102102     Document Type: Article

References (51)

1. Rosen ED, Spiegelman BM (2001) PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 276: 37731-37734.
2. Sharma AM, Staels B (2007) Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - Understanding obesity-related changes in regulation of lipid and glucose metabolism. Journal of Clinical Endocrinology & Metabolism 92: 386-395.
3. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, et al. (2013) PPAR gamma signaling and metabolism: the good, the bad and the future. Nature Medicine 19: 557-566.
4. Sugii S, Olson P, Sears DD, Saberi M, Atkins AR, et al. (2009) PPAR gamma activation in adipocytes is sufficient for systemic insulin sensitization. Proceedings of the National Academy of Sciences of the United States of America 106: 22504-22509.
5. Brun RP, Spiegelman BM (1997) PPAR gamma and the molecular control of adipogenesis. The Journal of endocrinology 155: 217-218.
6. Olefsky JM, Saltiel AR (2000) PPAR gamma and the treatment of insulin resistance. Trends in endocrinology and metabolism: TEM 11: 362-368.
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 355: 2427-2443.
8. DeFronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, et al. (2011) Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance. New England Journal of Medicine 364: 1104-1115.
9. Nissen SE, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. New England Journal of Medicine 356: 2457-2471.
10. Nissen SE, Wolski K (2010) Rosiglitazone Revisited An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality. Archives of Internal Medicine 170: 1191-1201.
11. Grey A, Bolland M, Gamble G, Wattie D, Horne A, et al. (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial. Journal of Clinical Endocrinology & Metabolism 92: 1305-1310.
12. Lu C-J, Sun Y, Muo C-H, Chen R-C, Chen P-C, et al. (2013) Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study. Cerebrovascular diseases (Basel, Switzerland) 36: 145-151.
13. Mitka M (2013) Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety. JAMA : the journal of the American Medical Association 310: 246-247.
14. Yamauchi T, Waki H, Kamon J, Murakami K, Motojima K, et al. (2001) Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. Journal of Clinical Investigation 108: 1001-1013.
15. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, et al. (2001) The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. Journal of Biological Chemistry 276: 41245-41254.
16. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nature genetics 20: 284-287.
17. Miles PD, Barak Y, He W, Evans RM, Olefsky JM (2000) Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. The Journal of clinical investigation 105: 287-292.
18. Lago RM, Singh PP, Nesto RW (2007) Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet (North American Edition) 370: 1129-1136.
19. Berger JP, Petro AE, MacNaul KL, Kelly LJ, Zhang BB, et al. (2003) Distinct properties and advantages of a novel peroxisome proliferator-activated protein gamma selective modulator. Molecular Endocrinology 17: 662-676.
20. Motani A, Wang Z, Weiszmann J, McGee LR, Lee G, et al. (2009) INT131: A Selective Modulator of PPAR gamma. Journal of Molecular Biology 386: 1301-1311.
21. Taygerly JP, McGee LR, Rubenstein SM, Houze JB, Cushing TD, et al. (2013) Discovery of INT131: A selective PPAR gamma modulator that enhances insulin sensitivity. Bioorganic & Medicinal Chemistry 21: 979-992.
22. Agrawal R, Jain P, Dikshit SN (2012) Balaglitazone: A Second Generation Peroxisome Proliferator-Activated Receptor (PPAR) Gamma (gamma) Agonist. Mini-Reviews in Medicinal Chemistry 12: 87-97.
23. Amato AA, Rajagopalan S, Lin JZ, Carvalho BM, Figueira ACM, et al. (2012) GQ-16, a Novel Peroxisome Proliferator-activated Receptor gamma (PPAR gamma) Ligand, Promotes Insulin Sensitization without Weight Gain. Journal of Biological Chemistry 287: 28169-28179.
24. Jain AN (2003) Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine. Journal of Medicinal Chemistry 46: 499-511.
25. Nugent C, Prins JB, Whitehead JP, Savage D, Wentworth JM, et al. (2001) Potentiation of glucose uptake in 3T3-L1 adipocytes by PPARgamma agonists is maintained in cells expressing a PPARgamma dominant-negative mutant: Evidence for selectivity in the downstream responses to PPARgamma activation. Molecular Endocrinology 15: 1729-1738.
26. Goto T, Nagai H, Egawa K, Kim Y-I, Kato S, et al. (2011) Farnesyl pyrophosphate regulates adipocyte functions as an endogenous PPAR gamma agonist. Biochemical Journal 438: 111-119.
27. Mendez R, Zheng Z, Fan Z, Rajagopalan S, Sun Q, et al. (2013) Exposure to fine airborne particulate matter induces macrophage infiltration, unfolded protein response, and lipid deposition in white adipose tissue. American Journal of Translational Research 5: 224-234.
28. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, et al. (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (North American Edition) 373: 2125-2135.
29. MacDonald MR, Petrie MC, Home PD, Komajda M, Jones NP, et al. (2011) Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study. Diabetes care 34: 1394-1396.
30. Okamoto Y, Kihara S, Funahashi T, Matsuzawa Y, Libby P (2006) Adiponectin: a key adipocytokine in metabolic syndrome. Clinical Science (London) 110: 267-278.
31. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, et al. (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). The Journal of biological chemistry 270: 12953-12956.
32. Miyazaki Y, Mahankali A, Wajcberg E, Bajaj M, Mandarino LJ, et al. (2004) Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. Journal of Clinical Endocrinology & Metabolism 89: 4312-4319.
33. Ohashi K, Ouchi N, Matsuzawa Y (2012) Anti-inflammatory and anti-atherogenic properties of adiponectin. Biochimie (Paris) 94: 2137-2142.
34. Takasawa K, Kubota N, Terauchi Y, Kadowaki T (2008) Impact of increased PPAR gamma activity in adipocytes in vivo on adiposity, insulin sensitivity and the effects of rosiglitazone treatment. Endocrine Journal 55: 767-776.
35. Cock T-A, Houten SM, Auwerx J (2004) Peroxisome proliferator-activated receptor-gamma: Too much of a good thing causes harm. EMBO Reports 5: 142-147.
36. Lehrke M, Lazar MA (2005) The many faces of PPAR gamma. Cell 123: 993-999.
37. Tontonoz P, Hu E, Graves RA, Budavari AI, Spiegelman BM (1994) mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer. Genes & development 8: 1224-1234.
38. Rival Y, Stennevin A, Puech L, Rouquette A, Cathala C, et al. (2004) Human adipocyte fatty acid-binding protein (aP2) gene promoter-driven reporter assay discriminates nonlipogenic peroxisome proliferator-activated receptor gamma ligands. Journal of Pharmacology and Experimental Therapeutics 311: 467-475.
39. Bhalla K, Hwang BJ, Choi JH, Dewi R, Ou L, et al. (2011) N-Acetylfarnesylcysteine Is a Novel Class of Peroxisome Proliferator-activated Receptor gamma Ligand with Partial and Full Agonist Activity in Vitro and in Vivo. Journal of Biological Chemistry 286: 41626-41635.
40. Halade GV, Williams PJ, Lindsey ML, Fernandes G (2011) Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacological Research 63: 300-307.
41. Dunn FL, Higgins LS, Fredrickson J, DePaoli AM, Grp INT (2011) Selective modulation of PPAR gamma activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. Journal of Diabetes and its Complications 25: 151-158.
42. Kubo M, Fukui M, Ito Y, Kitao T, Shirahase H, et al. (2014) Insulin Sensitization by a Novel Partial Peroxisome Proliferator-Activated Receptor gamma Agonist With Protein Tyrosine Phosphatase 1B Inhibitory Activity in Experimental Osteoporotic Rats. Journal of Pharmacological Sciences 124: 276-285.
43. Hemmeryckx B, Hoylaerts MF, Gallacher DJ, Lu HR, Himmelreich U, et al. (2013) Does rosiglitazone affect adiposity and cardiac function in genetic diabetic mice? European Journal of Pharmacology 700: 23-31.
44. Gregor MF, Hotamisligil GS (2011) Inflammatory Mechanisms in Obesity. Annual Review of Immunology, Vol 29 29: 415-445.
45. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation 112: 1796-1808.
46. Sun S, Ji Y, Kersten S, Qi L (2012) Mechanisms of Inflammatory Responses in Obese Adipose Tissue. In: Cousins RJ, editor. Annual Review of Nutrition, Vol 32. 261-261.
47. Ji Y, Sun S, Xia S, Yang L, Li X, et al. (2012) Short Term High Fat Diet Challenge Promotes Alternative Macrophage Polarization in Adipose Tissue via Natural Killer T Cells and Interleukin-4. Journal of Biological Chemistry 287: 24378-24386.
48. Prieur X, Mok CYL, Velagapudi VR, Nunez V, Fuentes L, et al. (2011) Differential Lipid Partitioning Between Adipocytes and Tissue Macrophages Modulates Macrophage Lipotoxicity and M2/M1 Polarization in Obese Mice. Diabetes 60: 797-809.
49. Li P, Lu M, Nguyen MTA, Bae EJ, Chapman J, et al. (2010) Functional Heterogeneity of CD11c-positive Adipose Tissue Macrophages in Diet-induced Obese Mice. Journal of Biological Chemistry 285: 15333-15345.
50. Kubo M, Motomura Y (2012) Transcriptional regulation of the anti-inflammatory cytokine IL-10 in acquired immune cells. Frontiers in immunology 3: 275-275.
51. Misra P, Chakrabarti R, Vikramadithyan RK, Gopalakrishnan B, Suresh J, et al. (2003) PAT5A: A partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. Journal of Pharmacology and Experimental Therapeutics 306: 763-771.